Clinical applications of coenzyme Q10

被引:138
作者
Garrido-Maraver, Juan [1 ,2 ]
Cordero, Mario D. [3 ]
Oropesa-Avila, Manuel [1 ,2 ]
Fernandez Vega, Alejandro [1 ,2 ]
de la Mata, Mario [1 ,2 ]
Delgado Pavon, Ana [1 ,2 ]
Alcocer-Gomez, Elisabet [1 ,2 ]
Perez Calero, Carmen [1 ,2 ]
Villanueva Paz, Marina [1 ,2 ]
Alanis, Macarena [1 ,2 ]
de lavera, Isabel [1 ,2 ]
Cotan, David [1 ,2 ]
Sanchez-Alcazar, Jose A. [1 ,2 ]
机构
[1] Univ Pablo Olavide, CABD, Consejo Super Invest Cient, Seville 41013, Spain
[2] Univ Pablo Olavide, Consejo Super Invest Cient, Ctr Invest Biomed Red Enfermedades Raras, Inst Salud Carlos III, Seville 41013, Spain
[3] Univ Seville, Fac Odontol, E-41009 Seville, Spain
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2014年 / 19卷
关键词
Coenzyme Q(10); clinical indications; pharmacokinetics; CoQ(10)-related compounds; review; TRIGGERS MITOCHONDRIA DEGRADATION; BLOOD MONONUCLEAR-CELLS; OXIDATIVE STRESS; DOUBLE-BLIND; Q(10) SUPPLEMENTATION; Q DEFICIENCY; BIOCHEMICAL RATIONALE; REDUCTASE INHIBITORS; HUNTINGTONS-DISEASE; FRIEDREICHS-ATAXIA;
D O I
10.2741/4231
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coenzyme Q10 (CoQ10) or ubiquinone was known for its key role in mitochondrial bioenergetics as electron and proton carrier; later studies demonstrated its presence in other cellular membranes and in blood plasma, and extensively investigated its antioxidant role. These two functions constitute the basis for supporting the clinical indication of CoQ10. Furthermore, recent data indicate that CoQ10 affects expression of genes involved in human cell signalling, metabolism and transport and some of the effects of CoQ10 supplementation may be due to this property. CoQ10 deficiencies are due to autosomal recessive mutations, mitochondrial diseases, ageing-related oxidative stress and carcinogenesis processes, and also a secondary effect of statin treatment. Many neurodegenerative disorders, diabetes, cancer, fibromyalgia, muscular and cardiovascular diseases have been associated with low CoQ10 levels. CoQ10 treatment does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. Oral CoQ10 treatment is a frequent mitochondrial energizer and antioxidant strategy in many diseases that may provide a significant symptomatic benefit.
引用
收藏
页码:619 / 633
页数:15
相关论文
共 156 条
[1]   Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM) [J].
Adarsh, K. ;
Kaur, H. ;
Mohan, V. .
BIOFACTORS, 2008, 32 (1-4) :145-149
[2]   Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency [J].
Aeby, A. ;
Sznajer, Y. ;
Cave, H. ;
Rebuffat, E. ;
Van Coster, R. ;
Rigal, O. ;
Van Bogaert, P. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (05) :827-827
[3]   Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases [J].
Beal, MF .
BIOFACTORS, 1999, 9 (2-4) :261-266
[4]  
Beg Sarwar, 2010, Recent Pat Drug Deliv Formul, V4, P245
[5]   Coenzyme Q10 and exercise training in chronic heart failure [J].
Belardinelli, Romualdo ;
Mucaj, Andi ;
Lacalaprice, Francesca ;
Solenghi, Maridia ;
Seddaiu, Giovanna ;
Principi, Federica ;
Tiano, Luca ;
Littarru, Gian Paolo .
EUROPEAN HEART JOURNAL, 2006, 27 (22) :2675-2681
[6]   Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes) [J].
Berbel-Garcia, A ;
Barbera-Farre, JR ;
Etessam, JP ;
Salio, AM ;
Cabello, A ;
Gutierrez-Rivas, E ;
Campos, Y .
CLINICAL NEUROPHARMACOLOGY, 2004, 27 (04) :187-191
[7]   Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics [J].
Bhagavan, HN ;
Chopra, RK .
FREE RADICAL RESEARCH, 2006, 40 (05) :445-453
[8]  
Bonakdar RA, 2005, AM FAM PHYSICIAN, V72, P1065
[9]   Chemotherapy induces an increase in coenzyme Q10 levels in cancer cell lines [J].
Brea-Calvo, G ;
Rodríguez-Hernández, A ;
Fernández-Ayala, DJM ;
Navas, P ;
Sánchez-Alcázar, JA .
FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (08) :1293-1302
[10]   UBIDECARENONE IN THE TREATMENT OF MITOCHONDRIAL MYOPATHIES - A MULTICENTER DOUBLE-BLIND TRIAL [J].
BRESOLIN, N ;
DORIGUZZI, C ;
PONZETTO, C ;
ANGELINI, C ;
MORONI, I ;
CASTELLI, E ;
COSSUTTA, E ;
BINDA, A ;
GALLANTI, A ;
GABELLINI, S ;
PICCOLO, G ;
MARTINUZZI, A ;
CIAFALONI, E ;
ARNAUDO, E ;
LICIARDELLO, L ;
CARENZI, A ;
SCARLATO, G .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1990, 100 (1-2) :70-78